| pubmed-article:9029189 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9029189 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9029189 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9029189 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:9029189 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:9029189 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:9029189 | lifeskim:mentions | umls-concept:C1552913 | lld:lifeskim |
| pubmed-article:9029189 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9029189 | pubmed:dateCreated | 1997-3-3 | lld:pubmed |
| pubmed-article:9029189 | pubmed:abstractText | Small pilot studies of patients with CML have reported on encouraging response rates after treatment with interferon-alpha (IFNalpha) in combination with low-dose cytosine arabinoside (LD ara-C). We therefore initiated a multi-center phase II trial in order to investigate the efficacy and tolerability of this combination in newly diagnosed patients with Ph-positive chronic myelogenous leukemia (CML). Eighty-four patients were treated with IFN-alpha-2c at daily subcutaneous doses of 3.5 MU and LD ara-C added subcutaneously for 10 days every month at a dose of 10 mg/m2, following an initial reduction of WBC to less than 20 x 10(9)/l with hydroxyurea (HU). Within a median observation period of 28 (5-59) months the patients received a median of 7 (1-35) IFNalpha and LD ara-C cycles. Treatment was stopped due to side effects in 16 cases (19%) and to primary or secondary treatment failure in 38 cases (45%). In 45 patients (54%) complete hematological response (CHR) was achieved; in 39 patients (46%) cytogenetic responses including 15 (18%) complete cytogenetic responses (CHR) were observed. Median duration of cytogenetic responses was 15 months. Relapses were seen in 8/15 patients (53%) with complete cytogenetic remission (CCR), in 3/6 patients (50%) with partial cytogenetic response and in 9/18 patients (50%) with minor cytogenetic response. In conclusion, the combination of IFNalpha and LD ara-C resulted in encouraging rates of hematological and cytogenetic responses in patients with CML with low to moderate toxicity. | lld:pubmed |
| pubmed-article:9029189 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9029189 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9029189 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9029189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9029189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9029189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9029189 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9029189 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9029189 | pubmed:issn | 0145-2126 | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:PontJJ | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:LinWW | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:LudwigHH | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:AbbrederisKK | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:NiessnerHH | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:LangAA | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:KonwalinkaGG | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:GrünewaldKK | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:LinkeschWW | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:HilbeWW | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:GeisslerDD | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:FridrikMM | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:GreigWW | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:SillHH | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:StögerMM | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:BernhartMM | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:ThalerJJ | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:NiederwieserD... | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:DubaCC | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:HausmaningerH... | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:SeewannHH | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:FluckingerTT | lld:pubmed |
| pubmed-article:9029189 | pubmed:author | pubmed-author:ApfelbeckUU | lld:pubmed |
| pubmed-article:9029189 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9029189 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:9029189 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9029189 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9029189 | pubmed:pagination | 75-80 | lld:pubmed |
| pubmed-article:9029189 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:meshHeading | pubmed-meshheading:9029189-... | lld:pubmed |
| pubmed-article:9029189 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9029189 | pubmed:articleTitle | Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. | lld:pubmed |
| pubmed-article:9029189 | pubmed:affiliation | Department of Internal Medicine, University Hospital, Innsbruck, Austria. | lld:pubmed |
| pubmed-article:9029189 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9029189 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9029189 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9029189 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9029189 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
